LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and ...

LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in Japan Mirum Pharmaceuticals ...

The approval of LIVMARLI in Japan marks a significant milestone for patients suffering from these rare cholestatic liver diseases. ALGS and PFIC are genetic disorders that can cause severe itching ...

Mirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) inhibitor, is approved for the treatment of cholestatic pruritus ...

The approval of LIVMARLI in Japan marks a significant milestone for patients suffering from these rare cholestatic liver diseases. ALGS and PFIC are genetic disorders that can cause severe itching and ...

Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...

Mirum Pharmaceuticals (MIRM) announced that its partner, Takeda (TAK), has received approval by the Japanese Ministry of Health, Labour, and ...

Mirum Pharmaceuticals, Inc. shows strong growth with a 43% revenue jump and promising pipeline assets. Click here for my ...